Congrats to Andreas and Yue for the best paper award! #eau24 sciencedirect.com/science/ar…
Günter Niegisch retweeted
JUST IN: @US_FDA alert: FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma! Via @ASCO @US_FDA alert !
Trial presented @myESMO #ESMO23 and published @NEJM
@OncoAlert @MattGalsky @sonpavde @MichvdHeijden
Günter Niegisch retweeted
No matter how you splice it , analyze it or criticize it .. this is hope .. something we have not been able to say in a very very long time for many of our #bladdercancer patients and I am here for it – at Richfield, OH
In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer, progression-free and overall survival nearly doubled with the experimental treatment. Full trial results: nej.md/49ViJEe
ALT Kaplan–Meier estimates of progression-free survival according to treatment group in the intention-to-treat population
Online now! Enfortumab Vedotin and Pembrolizumab — A New Perspective on Urothelial Cancer | NEJM nejm.org/doi/full/10.1056/NE…
Insightful case discussion with an outstanding panel at #emuc23 with @amerseburger @DrYukselUrun , Kerstin Junker, N.Sanmamed and H. Thoeny!
Günter Niegisch retweeted
CheckMate 901 folks #ESMO23 @BladderCancerUS @TischCancer @sonpavde @MichvdHeijden @DrYukselUrun
nejm.org/doi/full/10.1056/NE…
Günter Niegisch retweeted
#Goosebumps #EV302 #ESMO23
Took 3 decades but a new SOC in 1L bladder cancer !!!!!! @tompowles1
EV+Pembro irrespective…..WOW! 🤩
Günter Niegisch retweeted
🔥Breaking News at #ESMO2023!🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution #EV302. Terrific presentation by @tompowles1. 🙌🔬🎗️ @urotoday @OncoAlert @myESMO
Günter Niegisch retweeted
EV-302/Keynote-A39 game changer in mBCa
OS 31.5 mo vs 16.1 👏🏼
Standing ovations for @tompowles1
@OncoAlert @myESMO @Silke_Gillessen
Günter Niegisch retweeted
Latest Publication by our
Düsseldorf UroRad group
sciencedirect.com/science/ar…
Online now: DARO safety data in comorbid patients!
Efficacy and safety outcomes of darolutamide in patients with non-meta... sciencedirect.com/science/ar…
Günter Niegisch retweeted
🆕 Do not perform immediate cytoreductive nephrectomy in intermediate-risk patients who have an asymptomatic synchronous primary tumour and require systemic therapy.
#RenalCellCarcinoma #EAUguidelines
uroweb.org/guidelines/renal-…
Günter Niegisch retweeted
The addition of Talazoparib(PARPi) to enza in CRPC has most effect in BRCA+ve tumors. Effects in the remaining HRR population are marginal or -ve (e.g. ATM). This is largely consistent with previous data for PARPi in CRPC, supporting the ODAC decision on olaparib #ASCO2023
Günter Niegisch retweeted
A real pleasure and a great honour to spend 2 days # Dusseldorf University as invited professor by @ Prof. Peter Albers @Uroweb .A Great opportunity to perform a Robotic Radical Inguinal Lymphadenectomy for penile cancer and present our data from @FPuigvert
Excellent talk on penile cancer management by @DrJM_Gaya, our visiting professor at @HHU_de !
Out now! See the full publication on tailored immunotherapy in UC patients (TITAN TCC)!!
authors.elsevier.com/c/1ggI0…
Günter Niegisch retweeted
Brilliant tour de force by @TiansterZhang
What lies in 2L and beyond in the treatment of #mRCC ?
Amazing to see how far we have come and the prospects ahead!
#GU23 @OncoAlert
Günter Niegisch retweeted
Cabopoint prospectively explores cabo in ICI refactory disease. RR of 30% post ipi/nivo and 25% post VEGF/ICI therapy show sequencing these agents is of benifit. It strengthens the data for Cabo in this setting which joins axi and pazo with prospect data in this setting. #GU23
